OR WAIT null SECS
Huma has acquired AstraZeneca’s digital health platform, and AstraZeneca has become a shareholder of Huma in a partnership to accelerate digital-first patient care.
Huma announced on March 23, 2022 that it has partnered with AstraZeneca to scale and accelerate innovation for digital health. The companies will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate the adoption of decentralized clinical trials.
Huma already possesses technology that powers digital-first care, serving more than 1.8 million active patient users across more than 3000 hospitals and clinics. The technologies are designed to provide more efficient care delivery by connecting with clinical workflows.
AstraZeneca has invested in the development of its digital health platform AMAZE to improve the care and management of patients. The collaboration with Huma will combine with the strong foundation of AMAZE to accelerate digital-first care across therapeutic areas and launch SaMDs.
"This collaboration marks an important moment as it is a first for AstraZeneca in the digital health space as well as in the industry for chronic diseases and SaMDs in support of different treatments,” said Karan Arora, chief commercial digital officer of AstraZeneca, in a press release. “With Huma, we are accelerating AstraZeneca’s ambition to achieve earlier diagnosis and treatment for patients with chronic diseases so they can lead better, more fulfilling lives.”